U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07540897) titled 'A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)' on April 15.
Brief Summary: The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Narcolepsy Type 1
Intervention:
DRUG: ALKS 2680 Dose 1
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
DRUG: ALKS 2680 Dose 2
Participants will receive ALKS 2680 t...